Barclays: High tariffs may lead to higher drug prices and shortages in the United States, with consumers bearing the brunt.

Barclays analysts pointed out in a research report that the United States plans to impose tariffs of up to 200% on drugs, which could have a significant impact on the pharmaceutical industry in the long term. Such high tariffs will increase production costs, squeeze profit margins, and may lead to supply chain disruptions. This is likely to cause drug shortages and ultimately lead to higher drug prices for American consumers. However, the government may provide companies with a transition period of up to one and a half years to adjust before the tariffs are officially implemented, which could be a positive factor for the industry.